The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
Patients need to be administered SUNITINIB MALATE(Sutent) in order to be enrolled in the
surveillance.
Patients not administered SUNITINIB MALATE(Sutent).
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
